Pharmacogenomic Drug-Target Network Analysis Reveals Similarity Profiles Among FDA-Approved Cancer Drugs.

ABSTRACT: Background: Defining specific molecular targets for cancer therapeutics remains a significant challenge in oncology. Many Food and Drug Administration (FDA)-approved anticancer drugs have incomplete target profiles, which limits our understanding of their mechanisms of action and opportunities for drug application. In this context, this study aimed to establish novel, biologically meaningful relationships between anticancer drugs and protein-coding genes. Methods: We developed a pharmacogenomic method that integrates transcriptomic data with drug activity data from the NCI-60 cancer cell line panel to study the interactions between 124 FDA-approved anticancer drugs and 399 cancer-related genes. Through this analysis, we identified gene-drug relationships and created a biparti

SUBMITTER: Berral-Gonzalez A 

PROVIDER: S-EPMC12655765 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature